Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of Inventions Concerning an Inactivated Dengue Virus Vaccine and a Method and Kit for Detection of Dengue Virus, 80798 [2010-32235]
Download as PDF
80798
Federal Register / Vol. 75, No. 246 / Thursday, December 23, 2010 / Notices
contacting Kim Iverson, Public
Information Officer, South Atlantic
Fishery Management Council, 4055
Faber Place Drive, Suite 201, North
Charleston, SC 29405; telephone: (843)
571–4366 or toll free at (866) SAFMC–
10. Copies will also be available online
at https://www.safmc.net as they become
available.
Special Accommodations
These meetings are physically
accessible to people with disabilities.
Requests for sign language
interpretation or other auxiliary aids
should be directed to the Council office
(see ADDRESSES) 3 days prior to the start
of each meeting.
Dated: December 17, 2010.
Tracey L. Thompson,
Acting Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
[FR Doc. 2010–32217 Filed 12–22–10; 8:45 am]
BILLING CODE 3510–22–P
DEPARTMENT OF COMMERCE
National Oceanic and Atmospheric
Administration
RIN 0648–XA106
New England Fishery Management
Council; Public Meeting
National Marine Fisheries
Service (NMFS), National Oceanic and
Atmospheric Administration (NOAA),
Commerce.
ACTION: Notice; public meeting.
AGENCY:
The New England Fishery
Management Council’s (Council)
Groundfish Committee will meet to
consider actions affecting New England
fisheries in the exclusive economic zone
(EEZ).
DATES: The meeting will be held on
Wednesday, January 19, 2011 at 9 a.m.
ADDRESSES: The meeting will be held at
the Clarion Hotel, 1230 Congress Street,
Portland, ME 04102; telephone: (207)
774–5611; fax: (207) 871–0510.
Council address: New England
Fishery Management Council, 50 Water
Street, Mill 2, Newburyport, MA 01950.
FOR FURTHER INFORMATION CONTACT: Paul
J. Howard, Executive Director, New
England Fishery Management Council;
telephone: (978) 465–0492.
SUPPLEMENTARY INFORMATION: The items
of discussion in the committee’s agenda
are as follows:
The Multispecies (Groundfish)
Oversight Committee will begin
development of Framework 47 to the
Northeast Multispecies Fishery
Management Plan (FMP). Framework 47
mstockstill on DSKH9S0YB1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
18:06 Dec 22, 2010
Jkt 223001
will consider changes to the haddock
bycatch cap in the herring fishery. The
Committee will work on the
development of an amendment to the
FMP that will address issues related to
state-sponsored permit banks. The
Committee will also discuss the
initiation of an amendment to the FMP
to consider allocative effects, excessive
control of fishing privileges, and fleet
diversity objectives for the multispecies
fishery. Other business may also be
discussed.
The Committee’s recommendations
will be delivered to the full Council at
its meeting in Portsmouth, NH on
January 25–27, 2011.
Although non-emergency issues not
contained in this agenda may come
before this group for discussion, those
issues may not be the subject of formal
action during this meeting. Action will
be restricted to those issues specifically
identified in this notice and any issues
arising after publication of this notice
that require emergency action under
section 305(c) of the Magnuson-Stevens
Fishery Conservation and Management
Act, provided the public has been
notified of the Council’s intent to take
final action to address the emergency.
Special Accommodations
This meeting is physically accessible
to people with disabilities. Requests for
sign language interpretation or other
auxiliary aids should be directed to Paul
J. Howard (see ADDRESSES) at least 5
days prior to the meeting date.
Authority: 16 U.S.C. 1801 et seq.
Dated: December 17, 2010.
Tracey L. Thompson,
Acting Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
[FR Doc. 2010–32215 Filed 12–22–10; 8:45 am]
BILLING CODE 3510–22–P
Availability for Exclusive, NonExclusive, or Partially-Exclusive
Licensing of Inventions Concerning an
Inactivated Dengue Virus Vaccine and
a Method and Kit for Detection of
Dengue Virus
Department of the Army, DoD.
Notice.
AGENCY:
Announcement is made of the
availability for licensing of the
invention set forth in U.S. Patent
6,254,873 which issued July 3, 2001,
entitled ‘‘Inactivated Dengue Virus
Vaccine,’’ and U.S. Patent 6,190,859,
entitled ‘‘Method and Kit for Detection
PO 00000
Frm 00013
Fmt 4703
Sfmt 4703
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2010–32235 Filed 12–22–10; 8:45 am]
BILLING CODE 3710–08–P
DEPARTMENT OF DEFENSE
Department of the Army
Notice of Intent To Prepare a
Programmatic Environmental Impact
Statement (PEIS) for Land Acquisition,
South Texas Training Center (STTC), in
McMullen County, TX
National Guard Bureau,
Department of the Army, DoD.
ACTION: Notice of intent.
Department of the Army
SUMMARY:
For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
licensing issues, Dr. Paul Mele, Office of
Research and Technology Applications
(ORTA), (301) 619–6664, both at telefax
(301) 619–5034.
SUPPLEMENTARY INFORMATION: The
invention relates to an inactivated
dengue virus vaccine to immunize and
protect humans against dengue fever.
The vaccine is based on dengue viruses
which have been propagated to high
titers in suitable cells, purified and
inactivated under conditions which
destroy infectivity but preserve
immunogenicity, a high level of which
is demonstrated in animal models. Uses
of the inactivated dengue virus for
detecting antibodies to dengue and kits
therefore are also described.
FOR FURTHER INFORMATION CONTACT:
AGENCY:
DEPARTMENT OF DEFENSE
ACTION:
of Dengue Virus,’’ issued February 20,
2001. The United States Government, as
represented by the Secretary of the
Army, has rights to this invention.
ADDRESSES: Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
The Department of the Army
intends to prepare a PEIS to analyze the
environmental and socioeconomic
impacts associated with the proposed
land acquisition and use of
approximately 22,232 acres for
implementation of an RPMP and
mission activities in south Texas. The
proposed land area, currently in private
ownership, would become the STTC.
This action will support the training
requirements of the TXARNG units
located in central and south Texas. The
PEIS will analyze alternatives that are
deemed feasible to meet the purpose
and need for this Proposed Action.
SUMMARY:
E:\FR\FM\23DEN1.SGM
23DEN1
Agencies
[Federal Register Volume 75, Number 246 (Thursday, December 23, 2010)]
[Notices]
[Page 80798]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-32235]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Exclusive, Non-Exclusive, or Partially-Exclusive
Licensing of Inventions Concerning an Inactivated Dengue Virus Vaccine
and a Method and Kit for Detection of Dengue Virus
AGENCY: Department of the Army, DoD.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Announcement is made of the availability for licensing of the
invention set forth in U.S. Patent 6,254,873 which issued July 3, 2001,
entitled ``Inactivated Dengue Virus Vaccine,'' and U.S. Patent
6,190,859, entitled ``Method and Kit for Detection of Dengue Virus,''
issued February 20, 2001. The United States Government, as represented
by the Secretary of the Army, has rights to this invention.
ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command,
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick,
Frederick, MD 21702-5012.
FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul
Mele, Office of Research and Technology Applications (ORTA), (301) 619-
6664, both at telefax (301) 619-5034.
SUPPLEMENTARY INFORMATION: The invention relates to an inactivated
dengue virus vaccine to immunize and protect humans against dengue
fever. The vaccine is based on dengue viruses which have been
propagated to high titers in suitable cells, purified and inactivated
under conditions which destroy infectivity but preserve immunogenicity,
a high level of which is demonstrated in animal models. Uses of the
inactivated dengue virus for detecting antibodies to dengue and kits
therefore are also described.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2010-32235 Filed 12-22-10; 8:45 am]
BILLING CODE 3710-08-P